Selank without prescription: nothing to be prescribed
Buying Selank without prescription sounds like a workaround, and it is not one. Nobody is bypassing a gate here, because the gate was never built. There is no FDA approved Selank product in the United States for any indication, and there is no compounded Selank preparation either, so there is no prescription for a doctor to decline to write or to be persuaded into writing. The absence is the whole of the story.
That absence is easy to misread in both directions. It does not mean Selank has been prohibited: nothing has been scheduled, and possession is not the subject of enforcement. It also does not mean Selank has been cleared: no agency has assessed it as safe or effective for use in people in this country. Between prohibited and approved there is a large, poorly signposted space, and this compound sits in the middle of it.
What follows is the documentary position, with dates and sources, because most of what is written about Selank on this point is wrong in the same repeated way. If you have read that Selank is an FDA category 2 substance or banned from compounding, you have read something the FDA pages do not say.
We earn a commission if you buy through the link on this page, as set out in our affiliate disclosure. That is precisely why this page reports what the regulatory record contains rather than what would be convenient.
The three routes people mean, and which of them exist
People asking how to get Selank without a prescription usually have one of three pictures in mind. Only one is real.
The first is an approved medicine bought over the counter, the way an antihistamine is. That requires FDA approval and an over-the-counter monograph or an approved application. Selank has neither. There is no approved product, so there is nothing to sell over any counter.
The second is a compounded preparation from a pharmacy against a prescription, which is the route that exists for a number of substances that never had their own approved product. It depends on the substance being usable under section 503A, which in practice means the bulks list or the interim policy categories. Selank appears on neither. This is where it differs from NAD+, where a compounded route genuinely operates and the argument is only about what it costs, as our page on the NAD+ compounded route works through.
The third is research material: a vial sold to a buyer for laboratory use, labelled not for human consumption, with no clinical claims attached. That is what is for sale, and it is the position of the peptides covered on our pages for BPC-157 with no script to get and MOTS-c as unapproved rather than over the counter. The distinction those pages keep making is worth repeating here: unapproved and unrestricted are not the same word, and a market with no gatekeeper is not the same as a market that was checked and cleared.
| Route | What it requires | Selank |
|---|---|---|
| Approved product, prescription or OTC | An FDA approved application for the product | Does not exist for any indication |
| Compounded on a prescription | A substance a pharmacy may lawfully compound from | Not on the 503A bulks list. Nomination withdrawn |
| Research material | A seller making no human-use claims | Yes. This is the entire US market |
Three ways an unapproved substance can reach a person in the US. Only the third one carries Selank.
What FDA has actually published about Selank
Two FDA pages carry the whole of the position, and both are current. The first is the agency's list of bulk drug substances used in compounding under section 503A, which the site marks as content current as of 05/14/2026. That page describes a February 2019 final regulation placing six substances on the 503A bulks list, and a September 2019 proposed regulation that would add five more and decline 26 others. Selank is not mentioned anywhere on it.
The second is the page titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of 04/22/2026. It carries two tables. The upper one is headed bulk drug substances under category 2 of the interim policies, and each row has a date on which the substance was added to category 2. The lower one is headed bulk drug substances nominated but withdrawn, and FDA describes it as substances previously in category 2 of the interim policies whose nominations were withdrawn by the nominators. Its rows carry no date, because the entries are no longer live.
Selank acetate (TP-7) is in the lower table. Its neighbours there include AOD-9604, BPC-157, CJC-1295, Epitalon, GHK-Cu, KPV, Melanotan II, MOTs-C, Semax, thymosin alpha-1 and TB-500, which is to say most of the research peptide market. The category 2 table above it names cesium chloride, chloral hydrate, diethylstilbestrol, domperidone, edetate disodium, germanium sesquioxide, GHRP-2, GHRP-6, ibutamoren mesylate, ipamorelin acetate, kisspeptin-10, neomycin sulfate, quinacrine hydrochloride and tranilast. Selank is not in that table. Any page telling you otherwise is describing a list it has not read.
What FDA does say about Selank sits in the withdrawn table's second column, and it is worth quoting exactly once, in full, rather than paraphrasing: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans." That appears on the agency's compounding safety risks page.
Read it closely, because it is more precise than the summaries of it. FDA is not asserting that Selank harmed anyone. It is saying two things: that aggregation and peptide-related impurities create an immunogenicity risk for some routes of administration, and that the agency does not have the information it would need to say anything more definite. The first is a manufacturing and testing problem. The second is an evidence gap. Neither is a verdict, and neither is a clearance.
Is Selank legal to buy, and what the answer actually turns on
Is Selank legal to buy is the question everyone arrives with, and the answer has three parts. We are publishers rather than lawyers and none of this is legal advice, but the documentary position is not obscure.
Selank is not a controlled substance, so possession is not a scheduling question. What it is, in United States terms, is an unapproved new drug, and the regulatory weight of that falls on how a product is sold rather than on the buyer. A vial sold as a research chemical, labelled for laboratory use and carrying no claims about treating anything, is the form the domestic market takes for that reason, and enforcement here has historically followed those claims rather than buyers.
Importing is where the position is stated rather than inferred. FDA's personal importation page says that in most circumstances it is illegal for individuals to import drugs for personal use, and that if a drug is approved in another country but is an unapproved new drug in the US, it is illegal to import. Selank is registered as an anxiolytic in Russia and unapproved here, which puts an overseas order inside that sentence.
State law is the third part, and we will not generalise about it beyond one flat point: no state licence lets a pharmacy dispense Selank on a prescription while it sits on no bulks list, so a clinic offering to arrange one is describing something that cannot lawfully be done anywhere in the country.
What a prescription would have provided, and what replaces it
A prescription is not a piece of paper, it is a chain of accountable people: a prescriber carrying liability for the judgement, a pharmacist who can refuse, a manufacturer holding a specification and a recall obligation, a reporting system that aggregates adverse events, and a state board that can discipline any of them. The table below sets out each link and what stands in for it here.
Every one of those roles is vacant here, and the replacements are thinner than they look. The product specification becomes a batch certificate, genuinely useful and true of one batch on one date. The recall route becomes nothing. The complaint route becomes the vendor's policy and a chargeback.
None of that says the compound is dangerous, or that a prescription would have made it safe. It says who is carrying the risk, which here is one person only. Our safety guide makes the general version of the point, and it is why this site treats documentation as the substitute for oversight rather than a formality.
| What a prescription provides | Who provides it | What replaces it here |
|---|---|---|
| An assessment of whether it suits you | A prescriber carrying liability | You |
| A product and interaction check | A dispensing pharmacist | Whatever you have read |
| A product specification and stability data | A licensed manufacturer | A batch certificate for one lot |
| A recall if a batch fails | The manufacturer and FDA | Nothing |
| Adverse event reporting into a system | The prescriber and the manufacturer | Nothing formal |
| A complaint route with teeth | A state board of pharmacy | Vendor policy, then your card issuer |
The accountability chain a prescription creates, and what stands in for each link when there is no prescription.
Selank no prescription: what to check in place of a pharmacist
If nobody with a licence is checking the product, the certificate is the only check available, and it should be read for scope rather than glanced at for a percentage. FDA's concern was immunogenicity from aggregation and peptide-related impurities, so the tests that speak to it are the ones people skip past.
Purity by HPLC tells you how much of the material is the peptide and what fraction is something else. Identity by mass spectrometry tells you it is the right molecule: for Selank the expected monoisotopic mass is 751.43 Da, and a certificate reporting a measured mass close to that against the correct formula, C33H57N11O9, is doing real work. Endotoxin testing, the one most commonly absent, tells you whether the batch is clean enough for anything injected. A sterility screen tells you whether anything grew, and heavy metals testing covers elemental impurities a purity assay cannot see.
On the product we link, that scope changed during 2026, and the difference is instructive rather than damning. The February 2026 certificate for lot 29-01260229 reports 99.32% purity by HPLC-UV, identity confirmed at 751.47 Da against 751.43 expected, and a measured quantity of 12.29 mg in a 10 mg vial. It contains no endotoxin test, no sterility screen and no heavy metals analysis. The certificate for the current batch, 29-05260628, adds all three: bacterial endotoxin by kinetic LAL to USP Chapter 85 reporting under 0.20 EU/mL against a 0.5 EU/mL limit, a rapid sterility screen returning no growth, and ICP-MS heavy metals with lead, arsenic, cadmium and mercury below their limits, at 99.371% purity and 11.86 mg net content.
Both documents are lot specific, which is the point of them. Neither promises anything about the vial you are sent, so the question to put to a vendor is not whether it tests but which batch is shipping and what that batch's document covers. A supplier answering with a lot number is behaving like a supplier. One answering with a specimen certificate for the product line is answering something else.
What this page will not give you
No dosing, no schedules, no milligram figures, no route recommendations, here or anywhere else on this site for Selank. That is a settled editorial position. There is no approved labelling to base such figures on, the Russian registration does not supply one that transfers, and the compound is sold for laboratory use. A page that fills that gap with numbers manufactures exactly the false confidence the missing prescription route should have prevented.
What we will do is state the position accurately. Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, PubChem CID 11765600, with no FDA approval for any indication, no entry on any current bulks list, and a published FDA concern about immunogenicity alongside an admission that the agency lacks the information to say more. Anybody selling you certainty beyond that is selling you something the record does not contain.